Heparin-Induced Thrombocytopenia Treatment & Management
- Author: Sancar Eke, MD, FASN; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP more...
If heparin-induced thrombocytopenia (HIT) is suspected, the first step is to discontinue and avoid all heparin products immediately. An order to simply "discontinue heparin" may not necessarily prevent heparin exposure, because unfractionated heparin (UFH) is commonly used to flush catheters.
Warfarin may cause microthrombosis in patients with HIT. These patients typically present with an international normalized ratio (INR) greater than 4, which corresponds to severe protein C depletion. Initiation of warfarin should be postponed until substantial platelet recovery. Preferably, warfarin should not started before the platelet count exceeds 150 x 109/L.[1, 49] If warfarin has already been started, vitamin K should be given.
Platelet transfusions should be avoided in HIT, as they may increase the thrombogenic effect. Guidelines from the American College of Chest Physicians suggest limiting platelet transfusions to patients with severe thrombocytopenia who are experiencing bleeding or undergoing an invasive procedure with a high risk of bleeding.
Patients with HIT are at high risk for thrombotic events and should be treated with alternative anticoagulants, typically a direct thrombin inhibitor (DTI). The US Food and Drug Administration (FDA) has approved the DTI argatroban (Acova) for prophylaxis and treatment of thrombosis in patients with HIT. The DTI bivalirudin is approved for use in patients who are undergoing percutaneous coronary intervention (PCI) and have, or are at risk for, HIT or HIT with thrombosis (HITT). The DTI lepirudin was discontinued by the manufacturer in May 2012.
The indirect factor Xa inhibitor fondaparinux (Arixtra) is not approved for use in HIT, but some experts consider it an important treatment option, especially in stable, non–critically ill patients.[38, 50]
Another indirect factor Xa inhibitor, danaparoid, is no longer available in the United States but is used in Canada, Europe, and Australia. The ACCP recommends the use of fondaparinux in pregnant patients with HIT if danaparoid is not available, as this agent does not cross placenta.
Several novel oral anticoagulants exist (eg, rivaroxaban, dabigatran, apixaban). However, these agents have not been assessed for treatment of patients with HIT and none have FDA approval for use in HIT.[38, 63]
For patients with heparin-induced thrombocytopenia (HIT) who have only isolated thrombocytopenia, therapeutic doses of alternative anticoagulants should be continued until the platelet counts recover to a stable plateau. Because the risk of thrombosis remains high for 2-4 weeks after treatment is initiated, consideration should be given to continuing anticoagulant therapy with an alternative agent or warfarin for up to 4 weeks.
For HIT patients with thrombosis, therapy with an alternative anticoagulant should be followed by a transition to warfarin, but only after platelet counts have recovered to above 150 x 109/L. Oral anticoagulants should be initiated at low doses (eg, ≤ 5 mg/day of warfarin), and an overlap with a direct thrombin inhibitor for at least 5 days should be planned until the international normalized ratio (INR) has been in the therapeutic range for at least 48 hours. Anticoagulation is typically continued for 3 months.
For patients with a past history of HIT who no longer have circulating HIT antibodies, the American College of Chest Physicians suggests that short-term (intraoperative only) heparin can be used for cardiac surgery, but recommends bivalirudin or argatroban for cardiac catheterization or percutaneous coronary intervention. Patients with persistent HIT antibodies who require cardiac surgery should not receive heparin.[38, 37]
[Guideline] Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep. 126(3 suppl):311S-337S. [Medline]. [Full Text].
Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003 Nov 10. 163(20):2518-24. [Medline]. [Full Text].
Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994 Jan. 93(1):81-8. [Medline]. [Full Text].
Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood. 2005 Jan 1. 105(1):131-8. [Medline]. [Full Text].
Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol. 1989 Oct. 73(2):235-40. [Medline].
Anderson GP. Insights into heparin-induced thrombocytopenia. Br J Haematol. 1992 Apr. 80(4):504-8. [Medline].
Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000 Jul 1. 96(1):182-7. [Medline].
Warkentin TE, Sheppard JA, Heels-Ansdell D, Marshall JC, McIntyre L, Rocha MG, et al. Heparin-induced thrombocytopenia in medical surgical critical illness. Chest. 2013 Sep. 144(3):848-58. [Medline].
Heeger PS, Backstrom JT. Heparin flushes and thrombocytopenia. Ann Intern Med. 1986 Jul. 105(1):143. [Medline].
Doty JR, Alving BM, McDonnell DE, Ondra SL. Heparin-associated thrombocytopenia in the neurosurgical patient. Neurosurgery. 1986 Jul. 19(1):69-72. [Medline].
Rizzoni WE, Miller K, Rick M, Lotze MT. Heparin-induced thrombocytopenia and thromboembolism in the postoperative period. Surgery. 1988 Apr. 103(4):470-6. [Medline].
Ling E, Warkentin TE. Intraoperative heparin flushes and subsequent acute heparin-induced thrombocytopenia. Anesthesiology. 1998 Dec. 89(6):1567-9. [Medline].
Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005 Dec 1. 106(12):3791-6. [Medline]. [Full Text].
Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci. 1993 Apr. 305(4):208-15. [Medline].
Arepally G, Cines DB. Heparin-induced thrombocytopenia and thrombosis. Clin Rev Allergy Immunol. 1998 Fall. 16(3):237-47. [Medline].
Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med. 1999. 50:129-47. [Medline].
Warkentin TE, Eikelboom JW. Who is (still) getting HIT?. Chest. 2007 Jun. 131(6):1620-2. [Medline].
Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996 Nov. 101(5):502-7. [Medline].
Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol. 1997 Sep. 56(1):12-6. [Medline]. [Full Text].
Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol. 1993 Jun. 84(2):322-8. [Medline].
King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med. 1984 Apr. 100(4):535-40. [Medline].
Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest. 2006 Jun. 129(6):1407-16. [Medline]. [Full Text].
Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006 Nov 1. 108(9):2937-41. [Medline]. [Full Text].
Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005 Jul. 94(1):132-5. [Medline].
Greinacher A, Lubenow N. Heparin-induced thrombocytopenia. Arnout J, de Gaetano G, Hoylaerts M, et al, eds. Thrombosis: Fundamental and Clinical Aspects. Leuven, Belgium: Leuven University Press; 2003.
Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998 Oct. 35(4 suppl 5):9-16; discussion 35-6. [Medline].
Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001 Oct 2. 135(7):502-6. [Medline].
Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res. 2006. 118(2):165-76. [Medline].
Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost. 2004 Jun. 30(3):273-83. [Medline].
Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012 Nov 15. 120(20):4160-7. [Medline]. [Full Text].
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006 Apr. 4(4):759-65. [Medline].
Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010 Dec. 8(12):2642-50. [Medline].
Berry C, Tcherniantchouk O, Ley EJ, et al. Overdiagnosis of heparin-induced thrombocytopenia in surgical ICU patients. J Am Coll Surg. 2011 Jul. 213(1):10-7; discussion 17-8. [Medline].
[Guideline] Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb. 141(2 Suppl):e495S-530S. [Medline]. [Full Text].
[Guideline] Cuker, A; Crowther, M. 2013 Clinical Practice Guideline on the Evaluation and Management of Adults with Suspected Heparin-Induced Thrombocytopenia (HIT). American Society of Hematology Quick Reference Guides. Available at http://www.hematology.org/Clinicians/Guidelines-Quality/Quick-Reference.aspx. Accessed: October 2015.
Hein PA, Lembcke A, Rogalla P. Images in cardiovascular medicine. Multiple thrombosis with aortic occlusion after heparin-induced thrombocytopenia demonstrated by multislice computed tomography. Circulation. 2006 Feb 14. 113(6):e80-3. [Medline]. [Full Text].
Lee GM, Arepally GM. Heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2013. 2013:668-74. [Medline].
Meyer O, Salama A, Pittet N, Schwind P. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet. 1999 Oct 30. 354(9189):1525-6. [Medline].
Baroletti S, Hurwitz S, Conti NA, et al. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med. 2012 Jan. 125(1):44-9. [Medline].
Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood. 2010 Sep 9. 116(10):1761-6. [Medline].
Eichler P, Raschke R, Lubenow N, et al. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol. 2002 Mar. 116(4):887-91. [Medline].
Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1995 Dec. 104(6):648-54. [Medline].
Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993 Apr 1. 69(4):344-50. [Medline].
Look KA, Sahud M, Flaherty S, Zehnder JL. Heparin-induced platelet aggregation vs platelet factor 4 enzyme-linked immunosorbent assay in the diagnosis of heparin-induced thrombocytopenia-thrombosis. Am J Clin Pathol. 1997 Jul. 108(1):78-82. [Medline].
Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012 Mar 8. 119(10):2209-18. [Medline].
Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000 Mar. 20(3):318-29. [Medline].
Junqueira DR, Perini E, Penholati RR, Carvalho MG. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev. 2012 Sep 12. 9:CD007557. [Medline].
Levine RL, McCollum D, Hursting MJ. How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?. Chest. 2006 Sep. 130(3):681-7. [Medline]. [Full Text].
Mallik A, Carlson KB, DeSancho MT. A patient with 'spontaneous' heparin-induced thrombocytopenia and thrombosis after undergoing knee replacement. Blood Coagul Fibrinolysis. January 2011. (22) 1:73-5. [Medline].
Pongas G, Dasgupta SK, Thiagarajan P. Antiplatelet factor 4/heparin antibodies in patients with gram negative bacteremia. Thromb Res. August 2013. 132(2):217-20. [Medline].
Smythe MA, Warkentin TE, Stephens JL, Zakalik D, Mattson JC. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol. 2002 Sep. 71(1):50-2. [Medline]. [Full Text].
[Guideline] Theodore E. Warkentin, Andreas Greinacher, Andreas Koster and A. Michael Lincoff. Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008. 133:340-380. [Full Text].
Wrkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. AM J Med. 2008. 121(7):632. [Medline].
Zheng Y, Wang AW, Yu M, Padmanabhan A, Tourdot BE, Newman DK, et al. B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. Blood. 2014 Feb 6. 123(6):931-4. [Medline]. [Full Text].
Cosmi B. Current management of heparin-induced thrombocytopenia. Expert Rev Hematol. 2015 Sep 14. 1-13. [Medline].
Greinacher A. CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia. N Engl J Med. 2015 Jul 16. 373 (3):252-61. [Medline].
Audette MD, Glymph DC. Bivalirudin in off-pump coronary artery bypass graft in a patient with heparin-induced thrombocytopenia: a case report of its use. AANA J. 2015 Apr. 83 (2):116-22. [Medline].
Miyares MA, Davis KA. Direct-acting oral anticoagulants as emerging treatment options for heparin-induced thrombocytopenia. Ann Pharmacother. 2015 Jun. 49 (6):735-9. [Medline].
Obeng EA, Harney KM, Moniz T, Arnold A, Neufeld EJ, Trenor CC 3rd. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. J Pediatr. 2015 Jan. 166 (1):144-50. [Medline].
|2 points||1 point||0 points|
platelet nadir 20-100 × 109/L
platelet nadir 10-19× 109/L
platelet nadir < 10× 109/L
|Timing of platelet count fall||Clear onset on day 5-10, or =1 d if heparin exposure within past 30 d||Consistent with day 5-10 fall, but not clear (eg, missing platelet counts); onset after day 10; or fall = 1 day if heparin exposure 30-100 days ago||Platelet count fall =4 d without recent heparin exposure|
|Thrombosis or other sequelae||New thrombosis (confirmed); skin necrosis; acute systemic reaction after IV UHF bolus||Progressive or recurrent thrombosis; erythematous skin lesions; thrombosis suspected but not proven||None|
|Other causes of thrombocytopenia||None apparent||Possible||Definite|